Rexulti generioc?

What is a generic version of Rexulti?

Rexulti (brexpiprazole) is an atypical antipsychotic medication used to treat major depressive disorder (MDD) and schizophrenia. Despite its relatively modern approval in 2015, a generic version is not yet available in the market due to ongoing patent protection.

Why is there no generic version of Rexulti yet?

Rexulti is protected by patents held by Otsuka Pharmaceutical Co. Ltd. and Lundbeck A/S, the original manufacturers of the drug, until 2028 [1]. Patented medicines are not eligible for generic competition for a certain period, extending the period during which the original manufacturer maintains market exclusivity.

When can we expect a generic version of Rexulti?

The patent expiration for Rexulti is currently set for 2032. However, this timeline may change as patent owners can often extend patent protection through maintenance fees and patent office actions, potentially delaying generic entry [2]. As patent expiration draws near, generic manufacturers will likely seek FDA approval for their versions of the medication.

Why do generic versions matter?

Generic versions can provide lower-cost options for patients, increasing access to necessary medications, especially for those with limited healthcare budgets. Generic manufacturers also stimulate competition, which often leads to improved pricing for brand-name medications.

Regulatory considerations for generic versions of Rexulti

The FDA has specific requirements for generic medications, including identical bioequivalence studies comparing generic to branded products. When a generic version of Rexulti becomes available, the FDA will review these submissions to ensure they meet these requirements before granting approval.

Patient access to affordable medications

The ongoing efforts to challenge patents and make generic versions of medications like Rexulti reflect the tension between pharmaceutical companies and patient advocacy groups over access to affordable treatments. Patient advocacy organizations and governments may continue to lobby for policies promoting competition in the pharmaceutical market.

Sources:

[1] DrugPatentWatch.com - Rexulti (brexpiprazole) Patents

[2] FDA - Pharmaceutical Patent Term Restoration